Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae268 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Annelie Johansson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Antineoplastic Agents, Hormonal, Menopause. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ALF medicine, Stiftelsen Gösta Miltons donationsfond, King Gustav V Jubilee Clinical Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Estrogen receptor–positive breast cancer patients have a long-term risk of distant metastatic disease, and premenopausal patients have a higher risk. Randomized studies with long-term follow-up are essential to understand treatment benefit. We elucidated the long-term tamoxifen therapy benefit by menopausal status in the Stockholm tamoxifen trials with 20 years complete follow-up.
Methods
Secondary analysis of 1242 estrogen receptor–positive and HER2-negative patients that were randomly assigned to 2-5 years of 40 mg adjuvant tamoxifen or no endocrine therapy. Distant recurrence-free interval in tamoxifen-treated vs endocrine untreated patients was assessed by Kaplan–Meier, Cox proportional hazards regression, and time-varying analyses.
Results
In premenopausal patients, a statistically significant tamoxifen benefit was observed for lymph node–negative (adjusted hazard ratio [HR] = 0.46, 95% confidence interval [CI] = 0.24 to 0.87), progesterone receptor–positive (adjusted HR = 0.61, 95% CI = 0.41 to 0.91), and genomic low-risk tumors (adjusted HR = 0.47, 95% CI = 0.26 to 0.85) but only lasted beyond 10 years for genomic low-risk tumors. Postmenopausal patients showed long-term benefit for all good-prognosis markers including low-grade (adjusted HR = 0.55, 95% CI = 0.41 to 0.73), lymph node–negative (adjusted HR = 0.44, 95% CI = 0.30 to 0.64), progesterone receptor–positive (adjusted HR = 0.60, 95% CI = 0.44 to 0.80), Ki-67 low (adjusted HR = 0.51, 95% CI = 0.38 to 0.68), and genomic low-risk tumors (adjusted HR = 0.53, 95% CI = 0.37 to 0.74), and regardless of tumor size (≤20 mm: adjusted HR = 0.55, 95% CI = 0.39 to 0.77; >20 mm: adjusted HR = 0.64, 95% CI = 0.44 to 0.94). Premenopausal patients with no poor-prognosis tumor characteristics (clinical marker score = 0) showed early benefit and postmenopausal long-term benefit.
Conclusions
Our study suggests differential tamoxifen benefit by menopausal status. Improved long-term endocrine therapy prediction in premenopausal patients is needed and could involve molecular markers because standard tumor characteristics cannot predict benefit beyond 10 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden.
- Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, 171 64 Stockholm, Sweden.
- Institution of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University, 413 45 Gothenburg, Sweden.
- Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University, 581 83 Linköping, Sweden.
- Buck Institute for Research on Aging, Novato, CA 94945, United States.
- Department of Surgery, University of California San Francisco, San Francisco, CA 94115, United States.
ORCID-Profile: Annelie Johansson, Christina Yau, Christopher C Benz
Förderung
- ALF medicine
- Stiftelsen Gösta Miltons donationsfond
- King Gustav V Jubilee Clinical Research Foundation
- Cancerföreningen i Stockholm
- NCI NIH HHS
- Swedish Research Council
- NIH HHS
- California Breast Cancer Research Program
Zitieren
APA
Johansson, A., Dar, H., Nordenskjöld, A., Perez-Tenorio, G., Tobin, N. P., Yau, C., Benz, C. C., Esserman, L. J., van 't Veer, L. J., Nordenskjöld, B., Stål, O., Fornander, T., & Lindström, L. S. (2025). Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae268
Vancouver
Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, et al. Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae268
BibTeX
@article{Johansson2025,
author = {Johansson, Annelie and Dar, Huma and Nordenskjöld, Anna and Perez-Tenorio, Gizeh and Tobin, Nicholas P and Yau, Christina and Benz, Christopher C and Esserman, Laura J and van 't Veer, Laura J and Nordenskjöld, Bo and Stål, Olle and Fornander, Tommy and Lindström, Linda S},
title = {Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae268}
}
EUVIMED